Alvotech
ALVOW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $1.16M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVO
Q3 2022 vs. Q2 2022
How the institutions holding Alvotech changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 29 | 1 | 26 | −2 |
| Shares | 6.38M | 13.8K | 6.39M | +24.9K (+0.4%) |
| Value | $5.40M | $12.0K | $4.54M | −$844.0K (−15.7%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Alvotech at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sona Asset Management (US) LLC | 53,027 | $37.0K | 0.02% |
Sold out (3)
Institutions that held Alvotech at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Balyasny Asset Management LLC | 79,314 | $54.0K |
| Clear Street LLC | 650 | $1.00K |
| SkyView Investment Advisors, LLC | 1,250 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Alvotech at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exos Asset Management LLC | 13,833 | $12.0K |